Why research matters at Colorado Blood Cancer Institute

At Colorado Blood Cancer Institute, research is more than discovery. It is part of how care moves forward. Through its collaboration with Sarah Cannon Research Institute, CBCI is helping connect patients to emerging therapies, advance early-phase blood cancer research and contribute to national conversations shaping the future of oncology care.

At Colorado Blood Cancer Institute (CBCI), research helps connect patients to emerging therapies, supports innovation in blood cancer treatment and contributes to advances in cancer care.

That matters deeply in blood cancer care, where treatment is evolving at a remarkable pace. New therapies, treatment combinations, and care approaches continue to expand options for patients. In that environment, research is not only about discovery. It is also about access, helping connect patients to emerging options while shaping the future of cancer care. At CBCI, that work is supported through an embedded research infrastructure in collaboration with Sarah Cannon Research Institute (SCRI).

Kelly Mozzetta, regional director of oncology research operations for CBCI and SCRI at HCA HealthONE, said regulatory specialists, research coordinators, nurses, laboratory teams and physicians work closely together to bring clinical trials to patients across the Rocky Mountain region. Rather than operating separately, the research team is integrated into the day-to-day life of the organization and works together to support patients throughout their care journey.

That level of integration matters for patients. Clinical trials can offer access to therapies that may not otherwise be available, particularly for patients whose disease has relapsed or who have exhausted standard FDA-approved treatment options.

Just as important is the level of physician engagement. Mozzetta emphasizes that research involvement at CBCI is not limited to a small subset of providers. Instead, she describes strong engagement across the physician group, along with active work in complex and emerging areas such as early-phase blood cancer research and cellular therapy.

Joshua Gordon, manager of study operations at SCRI at HCA HealthONE, adds that CBCI is a leader in early phase blood cancer research and consistently ranks among the highest enrolling practices within the field.

The recent selection of an abstract by Dr. Peter Forsberg, a fellowship-trained, board-certified hematologist/oncologist with HCA HealthONE, for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world's largest oncology conferences, offers one example of that culture in action.

 ASCO is one of the most prominent conferences in cancer care, making abstract selection a meaningful marker of scientific contribution and national visibility. More broadly, it reflects the caliber of work taking place at CBCI and its role in larger conversations shaping oncology care.

Research plays a central role in advancing cancer care. Through its collaboration with SCRI, CBCI continues to contribute to clinical research while helping patients access emerging treatment options.

Learn more about our blood cancer care and find a doctor on the HealthOne blood cancer website.